Regeneron’s (REGN) “Market Perform” Rating Reaffirmed at Raymond James Financial

Raymond James Financial reissued their market perform rating on shares of Regeneron (NASDAQ:REGN) in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The analysts noted that the move was a valuation call.

A number of other research firms also recently weighed in on REGN. BidaskClub raised shares of Regeneron from a strong sell rating to a sell rating in a research note on Friday, January 26th. Royal Bank of Canada reaffirmed a hold rating and issued a $430.00 price target on shares of Regeneron in a research note on Thursday, December 14th. Argus dropped their price target on shares of Regeneron from $540.00 to $470.00 and set a buy rating on the stock in a research note on Thursday, December 28th. Deutsche Bank began coverage on shares of Regeneron in a research note on Tuesday, December 12th. They issued a hold rating and a $397.00 price target on the stock. Finally, JPMorgan Chase upped their price target on shares of Regeneron from $455.00 to $457.00 and gave the stock a neutral rating in a research note on Wednesday, January 24th. Three analysts have rated the stock with a sell rating, eighteen have assigned a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $449.49.

Shares of NASDAQ:REGN opened at $325.08 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82. Regeneron has a 12-month low of $313.53 and a 12-month high of $543.55. The firm has a market cap of $34,762.11, a price-to-earnings ratio of 23.36, a PEG ratio of 1.05 and a beta of 1.46.



Regeneron (NASDAQ:REGN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $1.05. Regeneron had a net margin of 20.41% and a return on equity of 28.48%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the previous year, the business earned $3.04 EPS. The company’s revenue was up 28.9% on a year-over-year basis. sell-side analysts forecast that Regeneron will post 19.2 earnings per share for the current fiscal year.

In other Regeneron news, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $350.02, for a total transaction of $700,040.00. Following the completion of the sale, the director now directly owns 14,000 shares in the company, valued at $4,900,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The disclosure for this sale can be found here. Insiders have sold 5,000 shares of company stock worth $1,705,640 over the last three months. Company insiders own 10.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in REGN. Renaissance Technologies LLC boosted its holdings in Regeneron by 516.8% during the fourth quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock valued at $217,892,000 after acquiring an additional 485,600 shares during the period. Two Sigma Advisers LP bought a new stake in Regeneron during the fourth quarter valued at about $143,255,000. HealthCor Management L.P. bought a new stake in Regeneron during the fourth quarter valued at about $122,187,000. Millennium Management LLC boosted its holdings in Regeneron by 136.6% during the fourth quarter. Millennium Management LLC now owns 478,244 shares of the biopharmaceutical company’s stock valued at $179,801,000 after acquiring an additional 276,154 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its stake in shares of Regeneron by 93.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 553,501 shares of the biopharmaceutical company’s stock valued at $208,094,000 after buying an additional 267,442 shares during the period. Institutional investors own 66.39% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Regeneron’s (REGN) “Market Perform” Rating Reaffirmed at Raymond James Financial” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://dakotafinancialnews.com/2018/04/13/regenerons-regn-market-perform-rating-reaffirmed-at-raymond-james-financial.html.

Regeneron Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Analyst Recommendations for Regeneron (NASDAQ:REGN)

Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply